目的 探讨芪参胶囊联合盐酸地尔硫卓治疗稳定型心绞痛临床疗效。方法 选取2018年2月-2019年2月在西宁市第三人民医院治疗的稳定型心绞痛患者94例，根据用药的差别分为对照组（47例）和治疗组（47例）。对照组患者口服盐酸地尔硫卓片，30 mg/次，3次/d；治疗组患者在对照组基础上口服芪参胶囊，0.9 g/次，3次/d。两组均治疗6周。观察两组患者临床疗效，同时比较治疗前后两组患者心绞痛发作次数和持续时间、SAQ各维度积分和血清学指标。结果 治疗后，对照组和治疗组临床有效率分别为80.85%和97.87%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者心绞痛发作次数和持续时间均显著减少（P<0.05），且治疗组患者心绞痛发作次数和持续时间明显少于对照组患者（P<0.05）。治疗后，两组患者SAQ各维度积分均显著升高（P<0.05），且治疗组患者SAQ各维度积分明显高于对照组患者（P<0.05）。治疗后，两组患者血清核因子抑制蛋白-κB（NF-κB）、髓过氧化物酶（MPO）、肌钙蛋白（CTnI）、S100钙结合蛋白A12（S100A12）、可溶性细胞间粘附分子-1（sICAM-1）水平均明显降低（P<0.05），且治疗组患者这些指标明显低于对照组患者（P<0.05）。结论 芪参胶囊联合盐酸地尔硫卓治疗稳定型心绞痛可有效控制患者症状发生，改善机体细胞因子水平，提高患者生活质量。

Objective To investigate the clinical efficacy of Qishen Capsules combined with diltiazem in treatment of stable angina pectoris. Methods Patients (94 cases) with stable angina pectoris in Xining Third People's Hospital from February 2018 to February 2019 were divided into control (47 cases) and treatment (47 cases) groups based on different treatments. Patients in the control group were po administered with Diltiazem Hydrochloride Tablets, 30 mg/time, three times daily. Patients in the treatment group were po administered with Qishen Capsules on the basis of the control group, 0.9 g/time, three times daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacy was evaluated, and the frequency and duration of angina pectoris, SAQ integral in different dimensions, the serological indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and in the control and treatment groups was 80.85% and 97.87%, respectively, and there were differences between two groups (P<0.05). After treatment, the frequency and duration of angina pectoris in two groups was significantly decreased (P<0.05), and which in the treatment group was significantly less than that in the control group (P<0.05). After treatment, the SAQ integral in different dimensions scores in two groups were significantly increased (P<0.05), and the scores in the treatment group were significantly higher than those in the control group (P<0.05). After treatment, the serum NF-κB, MPO, S100A12, CTnI and sICAM-1 levels in two groups were significantly decreased (P<0.05), and these serological indexes in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Qishen Capsules combined with diltiazem in treatment of stable angina pectoris can effectively control the symptoms of patients, improve the level of cytokines, and improve the quality of life.

R972